VRIGNAUD; Patricia

Patent Applications and Registrations

Patent applications and USPTO patent grants for VRIGNAUD; Patricia.The latest application filed is for "antitumour combinations containing a vegf inhibiting agent and irinotecan".

Company Profile

1.9.18

VRIGNAUD; Patricia - Combs la Ville FR
VRIGNAUD; Patricia - Paris FR

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
Antitumour Combinations Containing A Vegf Inhibiting Agent And Irinotecan App 20190275147 - BISSERY; Marie-Christine ; et al.	2019-09-12
Antitumoral Combination Comprising Cabazitaxel And Cisplatin App 20180153931 - BISSERY; Marie-Christine ; et al.	2018-06-07
Antitumor Combinations Containing Antibodies Recognizing Specifically Cd38 And Cyclophosphamide App 20170056496 - LEJEUNE; Pascale ; et al.	2017-03-02
Antitumor combinations containing antibodies recognizing specifically CD38 and melphalan Grant 9,259,406 - Lejeune , et al. February 16, 2	2016-02-16
Pediatric Uses Of Cabazitaxel App 20140350273 - SUKHVINDER; Sidhu S. ; et al.	2014-11-27
Antitumour Combinations Containing A Vegf Inhibiting Agent And Irinotecan App 20140127202 - BISSERY; Marie-Christine ; et al.	2014-05-08
Antitumoral Combination Comprising Cabazitaxel And Cisplatin App 20140056996 - BISSERY; Marie-Christine ; et al.	2014-02-27
Antitumor combinations containing antibodies recognizing specifically CD38 and vincristine Grant 8,633,301 - Lejeune , et al. January 21, 2	2014-01-21
Antitumor Combinations Containing A Vegf-inhibiting Agent And 5fu Or A Derivative Thereof App 20130184205 - Vrignaud; Patricia ; et al.	2013-07-18
Antitumor combinations containing a VEGF-inhibiting agent and 5FU or a derivative thereof Grant 8,388,963 - Vrignaud , et al. March 5, 2	2013-03-05
Antitumor Combination Including Ave8062 And Sorafenib App 20120108641 - DEMERS; Brigitte ; et al.	2012-05-03
Antitumor Combinations Containing Antibodies Recognizing Specifically Cd38 And Cytarabine App 20120093806 - Lejeune; Pascale ; et al.	2012-04-19
Antitumor Combinations Containing Antibodies Recognizing Specifically Cd38 And Cyclophosphamide App 20110305690 - Lejeune; Pascale ; et al.	2011-12-15
Antitumor Combinations Containing Antibodies Recognizing Specifically Cd38 And Vincristine App 20110293606 - Lejeune; Pascale ; et al.	2011-12-01
Antitumor Combinations Containing Antibodies Recognizing Specifically Cd38 And Melphalan App 20110274686 - Lejeune; Pascale ; et al.	2011-11-10
Combination Comprising Combretastatin and Anticancer Agents App 20110054035 - BISSERY; Marie-Christine ; et al.	2011-03-03
Combination comprising combretastatin and anticancer agents Grant 7,851,443 - Bissery , et al. December 14, 2	2010-12-14
Antitumour Combinations Containing A Vegf Inhibiting Agent And Irinotecan App 20100160233 - BISSERY; Marie-Christine ; et al.	2010-06-24
Antitumor Combinations Containing A Vegf-inhibiting Agent And 5fu Or A Derivative Thereof App 20090285841 - VRIGNAUD; Patricia ; et al.	2009-11-19
Antitumor Combinations Containing Taxane Derivatives App 20090196869 - BISSERY; Marie-Christine ; et al.	2009-08-06
Combination Comprising Combretastatin and Anticancer Agents App 20090023656 - BISSERY; Marie-Christine ; et al.	2009-01-22
Antitumor combinations containing a VEGF-inhibiting agent and 5FU or a derivative thereof App 20060178305 - Vrignaud; Patricia ; et al.	2006-08-10
Use of a taxoid to treat abnormal cell proliferation in the brain Grant 6,346,543 - Bissery , et al. February 12, 2	2002-02-12
Compositions containing at least one farnesyl transferase inhibitor and at least one topoisomerase inhibitor and compositions containing at least one farnesyl transferase inhibitor and at least one taxoid Grant 6,342,487 - Riou , et al. January 29, 2	2002-01-29

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.